

Skin vaccination Challenges & Opportunities


Vanessa Vankerckhoven, PhD Founder and CEO

September 17, 2024 Flanders Vaccine Symposium on Vaccine Delivery & Immune Response





1796

Dr Edward Jenner created the world's first successful vaccine. He found out that people infected with cowpox were immune to smallpox.










Why skin?

Skin is an overlooked optimal injection site

Skin is rich in immune cells

Men have a thicker dermis than women. Newborns have a thicker dermis than toddler, but thinner than adolescents.



Dose sparing opportunities | resolving shortages

Fractional vaccine dosage of only 1/5th to 1/10th of the IM/SC dose necessary for immunogenicity



Own data available for HepB^[1] and Rabies^[2] & literature for Polio^[3], Rabies^[4], HepA^[5], Flu^[6], Yellow Fever^[7], SARS-CoV-2^[8], MPX^[9]



"

As part of the response to the IPV shortage, PAHO/WHO recommended to implement the intradermal administration of one fraction of the complete IPV vaccine, specifically one fifth of the complete dose administered intramuscularly.

Arbo et al, 2019





"

As part of the response to the MPX health emergency, EMA/FDA implemented the intradermal administration of one fifth of the complete MPX vaccine, normally administered subcutaneously, to avoid a pandemic.









swollen lymph nodes



rush on face



low energy





muscle aches




fever





rush on legs





Learn more: www.cdc.gov/mpox

Technical complexity of injection in superficial skin

Up to 70% of injections performed incorrectly




Needle-stick injuries



Requires extensive training




Painful





Skin drug delivery devices



Alkilani et al. Pharmaceutics 2015




PharmaJet Tropis® ID



Becton Dickinson Intanza®



Nanopass MicronJet®



Microneedle patch







Our patented award-winning disruptive answer



Protected by 3 patent families



Controlled depth



Easy and safe



Low in pain





PHARMAPACK AWARD 2023
Patient Centric Design




Our key achievements and assets today



























VAX-ID® | Clinical Trial Hepatitis B vaccine fractional dose




- Fractional dose ID administration of a recombinant HepB vaccine showed a **non-inferior immune responses** as full dose IM administration.
- Local side effects were mild, only local redness at the injection site.







VAX-ID® | A promising solution for Personalised Medicine



- Viability and activation status of T cells was not affected upon injection (similar results for DCs).
- No differences were observed between a 27G needle, VAX-ID generation 2 (27G), VAX-ID generation 3 (27G) or ejection without needle.
- Promising results in light of cell-based therapies





VAX-ID and ROB-ID: a match made in heaven for pandemic readiness



VAX-ID and ROB-ID: a match made in heaven for pandemic readiness







Pre-clinical evaluation in artificial skin



Digital twin study to assess acceptability



